Articles by tag: alzheimers-treatment

Subcutaneous Lecanemab: FDA Priority Status 2026

FDA extended review of subcutaneous Lecanemab for therapy initiation. Learn about the new standard of home Alzheimer's treatment and approval forecasts.

Lecanemab in Alzheimer's disease: 27% slowing

Lecanemab is the first drug with full FDA approval that slows cognitive decline by 27%. Learn about efficacy, risks, and therapy availability.